BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares dropped 3.3% during trading on Monday . The stock traded as low as $2.26 and last traded at $2.31, with a volume of 389,847 shares. The stock had previously closed at $2.39.

A number of research analysts have recently issued reports on BDSI shares. FBR & Co reiterated a “buy” rating on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $4.00 price target (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Cantor Fitzgerald downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating and cut their price target for the company from $9.00 to $5.00 in a report on Wednesday, May 11th. Zacks Investment Research downgraded BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a report on Friday, May 6th. Finally, Roth Capital reiterated a “buy” rating on shares of BioDelivery Sciences International in a report on Monday, March 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $8.25.

The firm has a 50 day moving average price of $2.48 and a 200-day moving average price of $3.09. The firm’s market capitalization is $124.87 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. During the same quarter in the previous year, the business earned ($0.16) EPS. The firm had revenue of $3 million for the quarter, compared to the consensus estimate of $2.96 million. The firm’s revenue was down 77.1% compared to the same quarter last year. Equities analysts expect that BioDelivery Sciences International Inc. will post ($1.17) earnings per share for the current fiscal year.

Several hedge funds have bought and sold shares of the stock. Sei Investments Co. increased its stake in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares during the period. 1492 Capital Management LLC increased its stake in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares during the period. Bank of Montreal Can increased its stake in BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the period. Turner Investments L.P. increased its stake in BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the period. Finally, Russell Frank Co increased its stake in BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.